NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
June 24, 2026 — Quantum BioPharma's Lucid-MS enters phase 2 trials to halt multiple sclerosis progression. Learn how this novel therapy targets myelin repair, offering hope for millions living with MS.
June 24, 2026 — Quantum BioPharma advances Lucid-MS, a first-in-class drug for multiple sclerosis that protects myelin. Phase 2 trial preparation underway after successful safety studies.
June 24, 2026 — Onco-Innovations advances ONC010™, a nanoparticle PNKP inhibitor, targeting the $7B DDR oncology market. Preclinical success in colorectal cancer models and strategic partnerships highlight its potential. Learn more.
June 24, 2026 — Cardio Diagnostics (CDIO) announces Atlas Healthcare coverage for Epi+Gen CHD and PrecisionCHD tests, expanding access to AI-powered coronary heart disease risk assessment and diagnosis.
June 24, 2026 — Onco-Innovations partners with Nanosoft Polymers to advance ONC010, a nanoparticle PNKP inhibitor for solid tumors. Collaboration focuses on scalable polymer production and GMP readiness for clinical trials.
June 24, 2026 — Helus Pharma announces $50M public offering to fund Phase 3 depression trial (HLP003) and Phase 2 anxiety trial (HLP004). Cantor and Barclays lead the offering. Breakthrough therapy designation in play.
June 24, 2026 — Helus Pharma announces Phase 3 APPROACH trial for HLP003, a novel serotonergic agonist for major depressive disorder, surpasses 86% enrollment. Breakthrough Therapy Designation supports potential new depression treatment.
June 24, 2026 — VERAXA Biotech expands laboratory in Heidelberg to advance BiTAC platform and preclinical oncology programs, moving toward clinical development.
June 24, 2026 — LataMed AI Corp. partners with Focus Fitness in Venezuela to deploy digital health platforms for preventative care and fitness assessments, marking a milestone in wellness market expansion.
June 24, 2026 — Hong Kong's largest biotech delegation, led by HKSTP, heads to BIO 2026 in San Diego with 41 innovators, forging global partnerships in AI biotech, therapeutics, and diagnostics.
June 24, 2026 — A new American Heart Association statement reveals heart failure in pregnancy often mimics normal symptoms, delaying diagnosis. Learn risk factors, disparities, and why early detection is vital to save mothers' lives.
June 24, 2026 — Learn how OSHA defines confined spaces and why proper identification is key to workplace safety. DCS Rescue's article explains criteria, risks, and compliance for high-risk industries.
June 24, 2026 — Primaris Health soft opening reveals a proactive, personalized healthcare model focused on longevity. Learn about its multidisciplinary team, services, and vision for modern medicine.
June 24, 2026 — USPS employees lack short-term disability and paid parental leave, unlike other federal workers. Learn how private insurance can fill the gap and protect income during medical emergencies.
June 24, 2026 — Creative Biolabs offers iPSC-derived in vitro models for neurodegenerative disease research, including Alzheimer's, Parkinson's, and ALS. Learn how stem cell solutions advance drug discovery.
June 24, 2026 — Omega-3 fortified foods market projected to grow from USD 0.6B in 2025 to USD 1.8B by 2036 at 9.9% CAGR. Key players, trends, and regional insights from Future Market Insights.
June 24, 2026 — CollectionPro secures $207,575 federal arbitration victory under No Surprises Act, achieving 10.8x the payer's offer for a hospital facility fee dispute.
June 24, 2026 — Pharmaceutical Omega-3 API market projected to grow from $1.1B in 2026 to $2.3B by 2036 at 7.7% CAGR. Driven by prescription cardiovascular therapies, icosapent ethyl, and regulatory-ready APIs.
June 24, 2026 — ioBrite Gentle tooth whitening gel offers zero sensitivity, professional strength whitening for sensitive teeth. Backed by a zero-sensitivity guarantee, it's enamel-safe and available online.
June 23, 2026 — Heidelberg Pharma AG reports 98.67% approval at 2026 Annual General Meeting, elects Jack Yefei Ling to Supervisory Board, and advances ATAC technology for cancer therapies.